Unknown

Dataset Information

0

Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis.


ABSTRACT: Chorea-Acanthocytosis (ChAc) is a devastating, little understood, and currently untreatable neurodegenerative disease caused by VPS13A mutations. Based on our recent demonstration that accumulation of activated Lyn tyrosine kinase is a key pathophysiological event in human ChAc cells, we took advantage of Vps13a-/- mice, which phenocopied human ChAc. Using proteomic approach, we found accumulation of active Lyn, γ-synuclein and phospho-tau proteins in Vps13a-/- basal ganglia secondary to impaired autophagy leading to neuroinflammation. Mice double knockout Vps13a-/- Lyn-/- showed normalization of red cell morphology and improvement of autophagy in basal ganglia. We then in vivo tested pharmacologic inhibitors of Lyn: dasatinib and nilotinib. Dasatinib failed to cross the mouse brain blood barrier (BBB), but the more specific Lyn kinase inhibitor nilotinib, crosses the BBB. Nilotinib ameliorates both Vps13a-/- hematological and neurological phenotypes, improving autophagy and preventing neuroinflammation. Our data support the proposal to repurpose nilotinib as new therapeutic option for ChAc patients.

SUBMITTER: Peikert K 

PROVIDER: S-EPMC8091687 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3217364 | biostudies-literature
| S-EPMC4629413 | biostudies-literature
| S-EPMC3324182 | biostudies-literature
| S-EPMC5498799 | biostudies-literature
| S-EPMC6353409 | biostudies-literature
| S-EPMC4615612 | biostudies-literature
| S-EPMC8370142 | biostudies-literature
| S-EPMC7275941 | biostudies-literature
| S-EPMC3818425 | biostudies-literature
| S-EPMC6177277 | biostudies-literature